,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2013-02-08 06:40:00,"Teva Pharmaceutical Industries ( TEVA ) reported fourth quarter earnings of $1.32 per American Depositary Share (ADS), a penny short of the Zacks Consensus Estimate and 17% below the year-ago earnings.",0.021524323150515556,0.9637691378593445,0.014706519432365894,negative,-0.942244827747345
1,2013-02-08 06:40:00,"Fourth quarter revenues declined 7.5% to $5.25 billion, missing the Zacks Consensus Estimate of $5.27 billion.",0.01767496019601822,0.9741715788841248,0.008153453469276428,negative,-0.9564965963363647
2,2013-02-08 06:40:00,"Full year earnings came in at $5.35 per ADS, a penny below the Zacks Consensus Estimate but 7.6% above 2011 earnings.",0.1074438989162445,0.8392964601516724,0.05325963348150253,negative,-0.7318525314331055
3,2013-02-08 06:40:00,"Full year revenues increased 10.9% to $20.32 billion, shy of the Zacks Consensus Estimate of $20.33 billion.",0.9461125135421753,0.0339503213763237,0.019937219098210335,positive,0.912162184715271
4,2013-02-08 06:40:00,Teva reported revenue growth only in Europe (up 2%) in the reported quarter.,0.8106640577316284,0.028625961393117905,0.16071006655693054,positive,0.7820380926132202
5,2013-02-08 06:40:00,Revenues declined in the US (down 14%) and RoW (down 3%).,0.017414389178156853,0.9711675047874451,0.0114181749522686,negative,-0.9537531137466431
6,2013-02-08 06:40:00,Currency fluctuations negatively impacted total revenues by $50 million.,0.01680145412683487,0.9665900468826294,0.016608553007245064,negative,-0.9497885704040527
7,2013-02-08 06:40:00,"Revenues in the US fell 14% to $2.6 billion in the reported quarter, mainly due to the genericization of Provigil in 2012 and higher generic revenues in the year-ago quarter.",0.016365783289074898,0.9744458794593811,0.0091883959248662,negative,-0.9580801129341125
8,2013-02-08 06:40:00,"The US generic business posted revenues of $1.0 billion, down 17%.",0.017941121011972427,0.9704709053039551,0.011587953194975853,negative,-0.952529788017273
9,2013-02-08 06:40:00,Revenues in the year-ago quarter were much higher due to major launches in that quarter.,0.93560791015625,0.019260169938206673,0.0451318584382534,positive,0.9163477420806885
10,2013-02-08 06:40:00,"During 2012, Teva launched 23 new generic products and expects to launch a similar number of products in 2013.",0.4618093967437744,0.0077915801666677,0.530398964881897,neutral,0.4540178179740906
11,2013-02-08 06:40:00,Specialty product revenues declined 7% to $2.1 billion in the fourth quarter of 2012.,0.01746235601603985,0.9729949831962585,0.009542714804410934,negative,-0.9555326104164124
12,2013-02-08 06:40:00,"Revenues were negatively impacted by the genericization of Provigil which posted revenues of $25 million, down 93% from the year-ago quarter.",0.017163915559649467,0.9728904962539673,0.009945646859705448,negative,-0.9557265639305115
13,2013-02-08 06:40:00,"Meanwhile, products like Treanda ($161 million, up 23%), Copaxone ($1.1 billion, up 14%) and Azilect ($86 million, up 4%) contributed to growth.",0.9463445544242859,0.016752557829022408,0.03690290078520775,positive,0.9295920133590698
14,2013-02-08 06:40:00,Copaxone revenues benefited from the take-back of distribution and marketing rights in Europe from Sanofi ( SNY ).,0.8834722638130188,0.011057022958993912,0.10547066479921341,positive,0.8724152445793152
15,2013-02-08 06:40:00,"Teva intends to file for approval of a 40 mg thrice-weekly (3TW - three times a week) formulation of Copaxone in Mar 2013, followed by potential launch a year thereafter.",0.36224672198295593,0.008631551638245583,0.629121720790863,neutral,0.3536151647567749
16,2013-02-08 06:40:00,"Meanwhile, respiratory segment revenues declined 7% to $256 million.",0.016771454364061356,0.9735071659088135,0.009721368551254272,negative,-0.9567357301712036
17,2013-02-08 06:40:00,"The women's health business recorded revenues of $132 million, up 42%.",0.9452285766601562,0.017928067594766617,0.03684334084391594,positive,0.9273005127906799
18,2013-02-08 06:40:00,Revenues in Europe increased 2% to $1.5 billion.,0.9573682546615601,0.017710281535983086,0.02492155134677887,positive,0.939657986164093
19,2013-02-08 06:40:00,Strong Copaxone revenues and higher revenues from the OTC business drove performance.,0.9511047601699829,0.019610175862908363,0.02928503230214119,positive,0.9314945936203003
20,2013-02-08 06:40:00,European generic revenues of $930 million declined 5% from the year-ago period.,0.01813179813325405,0.973646342754364,0.008221913129091263,negative,-0.9555145502090454
21,2013-02-08 06:40:00,"Teva is working on improving its diversity, reach and flexibility in Europe.",0.9386171102523804,0.014261768199503422,0.04712113365530968,positive,0.9243553280830383
22,2013-02-08 06:40:00,"RoW (Rest of the World including Canada, Israel, certain markets in Eastern Europe, Latin America and Asia) revenues slipped 3% during the quarter to $1.1 billion.",0.01715969666838646,0.9737780690193176,0.009062329307198524,negative,-0.9566183686256409
23,2013-02-08 06:40:00,"Although performance was strong in Latin America, weaker performance in Canada (due to government-imposed price reforms) and the sale of certain businesses of Mepha AG affected revenues.",0.0209826547652483,0.9663801789283752,0.012637119740247726,negative,-0.9453974962234497
24,2013-02-08 06:40:00,API revenues increased 3% to $202 million.,0.9539381861686707,0.017633771523833275,0.028428100049495697,positive,0.9363043904304504
25,2013-02-08 06:40:00,OTC revenues increased 24% to $269 million.,0.9562492966651917,0.017443057149648666,0.0263076052069664,positive,0.9388062357902527
26,2013-02-08 06:40:00,Teva has a partnership agreement with Procter & Gamble ( PG ) targeting the consumer health care market.,0.8179993033409119,0.011319614015519619,0.17068113386631012,positive,0.8066796660423279
27,2013-02-08 06:40:00,Research & Development expense increased to $374 million from $371 million in the year-ago period.,0.8014264702796936,0.17541973292827606,0.023153839632868767,positive,0.6260067224502563
28,2013-02-08 06:40:00,"Meanwhile, Selling and Marketing (S&M) expenditures increased to $1,043 million from $1,025 million.",0.9555068016052246,0.025057127699255943,0.019436065107584,positive,0.9304496645927429
29,2013-02-08 06:40:00,The company bought back 12.7 million shares during the quarter for about $0.5 billion.,0.27938443422317505,0.017222557216882706,0.7033929824829102,neutral,0.26216188073158264
30,2013-02-08 06:40:00,Teva has a $3 billion share buyback program which was announced in December 2011.,0.43476733565330505,0.007305511273443699,0.5579271912574768,neutral,0.4274618327617645
31,2013-02-08 06:40:00,Teva also announced a 15% hike in quarterly dividend.,0.9039623737335205,0.03707074746489525,0.05896691605448723,positive,0.866891622543335
32,2013-02-08 06:40:00,We are positive on the company returning value to shareholders.,0.8560531735420227,0.012448303401470184,0.13149850070476532,positive,0.8436048626899719
33,2013-02-08 06:40:00,The company maintained its outlook for 2013.,0.08262687921524048,0.0065579903312027454,0.9108151197433472,neutral,0.07606888562440872
34,2013-02-08 06:40:00,Teva expects to earn $4.85 - $5.15 per ADS on total net revenues of $19.5 - $20.5 billion.,0.11439599096775055,0.008137403056025505,0.87746661901474,neutral,0.1062585860490799
35,2013-02-08 06:40:00,"The Zacks Consensus Estimate for earnings and revenues currently stand at $5.10 per ADS and $20.2 billion, respectively.",0.018781401216983795,0.01132132112979889,0.9698973298072815,neutral,0.007460080087184906
36,2013-02-08 06:40:00,The company said that it intends to sell its Irvine manufacturing facility.,0.017036886885762215,0.04582205414772034,0.9371410012245178,neutral,-0.028785167261958122
37,2013-02-08 06:40:00,We believe a deal will be announced shortly.,0.20354387164115906,0.006918666884303093,0.7895374298095703,neutral,0.19662520289421082
38,2013-02-08 06:40:00,Teva is going through a transition period.,0.08353237062692642,0.007867072708904743,0.9086005091667175,neutral,0.07566529512405396
39,2013-02-08 06:40:00,"Headwinds include EU pricing pressure, potential new competition for branded products (especially Copaxone) and fewer generic product launches compared to 2012.",0.01965993270277977,0.9644954800605774,0.015844635665416718,negative,-0.9448355436325073
40,2013-02-08 06:40:00,"With the company not including the impact of its cost-savings plan in its guidance, we believe Teva has left some room for delivering above expectations.",0.8750798106193542,0.023215191438794136,0.10170495510101318,positive,0.8518646359443665
41,2013-02-08 06:40:00,Share buybacks also leave some room for upside.,0.530745804309845,0.1014503538608551,0.3678038418292999,positive,0.42929545044898987
42,2013-02-08 06:40:00,Teva carries a Zacks Rank #3 (Hold).,0.04138132929801941,0.010659009218215942,0.9479596614837646,neutral,0.030722320079803467
43,2013-02-08 06:40:00,Mylan ( MYL ) currently looks more attractive with a Zacks Rank #2 (Buy).,0.6439274549484253,0.02459876984357834,0.33147382736206055,positive,0.6193286776542664
44,2013-02-08 06:40:00,"Meanwhile, Procter & Gamble is also a Zacks Rank #2 stock.",0.6373376846313477,0.029519354924559593,0.333143025636673,positive,0.6078183054924011
45,2013-02-08 06:40:00,", Sanofi is a Zacks Rank #1 (Strong Buy) stock.",0.534282922744751,0.012459567748010159,0.4532574713230133,positive,0.5218233466148376
46,2013-02-08 06:40:00,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
47,2013-02-08 06:40:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
